Birmingham AL, February 28, 2023 - Compression Works, Inc., a medical device company and manufacturer of the Abdominal Aortic & Junctional Tourniquet – Stabilized (AAJT-S) for the treatment of non-compressible hemorrhages in the global EMS and Military markets, announced they had named Bob Huebner as the company’s new National Director of Training.
Compression Works
Newsroom
A study published from the combined efforts of the National Academy of Medical Sciences of Ukraine in Kyiv, the Military Medical Teaching Center of the Northern Region in Kharkiv, the Kharkiv National Medical University, and Poltava State Medical University in World of Medicine and Biology in December 2024 demonstrated high levels of vascular occlusion with the Abdominal Aortic & Junctional Tourniquet-Stabilized (AAJT-S) by Compression Works, Inc.
The purpose of this study was to conduct a scientific analysis of applying different methods of temporary compression of the aorta in a combat surgical trauma setting. Seventy-six cases of temporary aortic occlusion were performed during evacuation procedures, with statistical and expert analysis conducted on the entire data set.
The results demonstrated that 57.1% of the procedures attempted with the AAJT-S controlled the bleeding, while 54.2% of the procedures attempted with an aortic vascular clamp placed during an open thoracotomy were successful. The only procedure attempted with REBOA did not control the bleeding.
The authors stated that the AAJT-S, which is externally applied around the abdomen, can be placed by any medical responder at the point of injury, does not require the participation of a qualified specialist, and should be used when providing “basic” pre-hospital assistance.
“The widespread use of the AAJT-S in Ukraine contributed to a significant increase in the resuscitated group at the early hospital stage,” said Dr. Panasenko. “There is a clear palliative orientation, and the AAJT-S should be used in the evaluation of non-medical, non-specialized transport, namely CASEVAC missions. The AAJT-S has a simple tightening system and provides for a large area of effective compression pressure with a high degree of accuracy and reliability,” said the users of the device. “In addition, the AAJT-S demonstrated the ability to maintain efficiency when the casualty was in a closed space, during rescue, dragging, and hasty evacuation procedures. We also found the device to be effective in stabilizing the pelvis in addition to its bleeding management capabilities,” said Dr. Panasenko.
The authors also cited that there is currently no evidence that REBOA increases survival or improves treatment results compared to resuscitative thoracotomy, and that REBOA may actually increase mortality, as reported in several recent studies in the published literature.
All methods of temporary occlusion of the aorta may act as a “bridge procedure” prior to final operative hemostasis and may be most effective when utilized in different settings.
“We are pleased with the battlefield success of the AAJT-S in assisting Ukraine in their war with Russia,” stated Dr. John Croushorn, Chief Medical Officer for Compression Works and inventor of the AAJT. “It is critical to stop bleeding at the point of wounding so that the casualty can be stabilized and transported to definitive care,” said Croushorn.
“Compression Works has been at the forefront of battlefield care since the invasion, and the data continues to come back resoundingly positive that severe hemorrhage control is paramount to prolonged casualty care and resuscitation efforts,” said Dr. Croushorn.
About Compression Works
Compression Works develops the AAJT-S, a multi-use medical device addressing the most pressing needs of emergency and battlefield medicine. Trusted by the U.S. military, trauma centers, EMS, and law enforcement, Compression Works is a veteran-owned business proudly manufacturing lifesaving solutions in the USA.
HEMORRHAGE STOPS HERE!
Scott Dodson, CEO
Compression Works
1 800-988-4052
John Croushorn MD, FACEP, CMO
1-800-988-4052
Visit us on social media:
Birmingham AL, July 14, 2022, Compression Works Inc., the medical device company that created the Abdominal Aortic and Junctional Tourniquet – Stabilized (AAJT-S) for the treatment of non-compressible hemorrhages in the global EMS and military markets, welcomes Scott Garrett as its new Chief Operating Officer.
Dallas TX, May 18, 2022, Compression Works is in the middle of raising a $2 million convertible note, of which Dodson said it has closed about 75%. With the new funding, the company will be bringing on new team members to expand its production capabilities and find new clients in the field.
Birmingham AL, May 03, 2022, Compression Works, creators of the Abdominal Aortic and Junctional Tourniquet-Stabilized (AAJT-S) device, announces the publication of a new trauma review article in the Annals of Emergency Medicine, “External Aortic Compression in Noncompressible Truncal Hemorrhage and Traumatic Cardiac Arrest: A Scoping Review.” The study examines aortic compression as it relates to non-compressible truncal hemorrhage and traumatic cardiac arrest subjects.
Birmingham AL, April 04, 2022, Compression Works, Inc. maker of the Abdominal Aortic and Junctional Tourniquet-Stabilized (AAJT-S) device, announces a relief effort to support the people of Ukraine with its life-saving hemorrhage control solution. The AAJT-S devices are intended to help warfighters and civilians who have been injured as a result of the Russia invasion.
Birmingham AL, December 20, 2021, Compression Works, creators of the life-saving Abdominal Aortic and Junctional Tourniquet-Stabilized (AAJT-S) device, has dramatically increased their pre-hospital EMS distribution capabilities across the United States.
The AAJT-S is cleared by the FDA, CE marked for sale outside of the U.S., meets the CoTCCC criteria, and has been vetted, studied and published by the Institute for Surgical Research (ISR) and the 59th Med Wing of the U.S. Air Force researchers in San Antonio, Texas. The Compression Works device is also featured in over 64 peer reviewed publications in the literature.
The Abdominal Aortic and Junctional Tourniquet–Stabilized (AAJT-S) that treats both pelvic hemorrhage and severe bilateral lower junctional hemorrhage has been approved for use by paramedics and other first-responders in Alabama.
Tactical medics worldwide use the Abdominal Aortic and Junctional Tourniquet–Stabilized (AAJT-S) to control hemorrhage from armpit, groin and pelvic injuries.
The AAJT-S continues to be the only junctional and true truncal tourniquet to have saved life in upper and lower junctional hemorrhage.
Noncompressible torso hemorrhage is recognized as the leading cause of death in trauma, but definitive hemorrhage control has been challenging.
Croushorn’s fanny pack-like tourniquet (which won a 2012 Popular Science invention award) received FDA approval in 2011 and saved its first two lives this summer.
